Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab
Perets, Ruth, Meshner, Shiri, Tirosh, Osnat, Eshar, Shiri, Metz-Breiner, Alona, Kruger Ben-Shabat, Sheerli, Ben-Yehuda, Hila, Haber, Elran, Cohen-Asis, Meital, Maurice-Dror, Corinne, Ringel, Yehuda, Holland, Roy, Shirman, Yelena, Shentzer kutiel, Talia
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
BMC128: A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors
Maurice-Dror, Corinne, Tirosh, Osnat, Kruger Ben-Shabat, Sheerli, Eshar, Shiri, Plolonsky, Omri, Davis, Noa, Haber, Elran, Meshner, Shiri, Perets, Ruth
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article